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Results from recent studies have shown that a1A-adrenergic receptor (a1A-AR) antagonists could offer a new alternative in the
treatment of preterm delivery. However, members of this group [2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane
hydrochloride (WB4101), 5-methylurapidil (5-MU)] are known to in¯uence serotonin (5-hydroxy-tryptamine) (5-HT1A) recep-
tors, too. Our objective was to clarify the role of their 5-HT1A activities in the uterus relaxant effect. RT±PCR was used to
determine mRNA expression of the receptor subtypes in 22 day pregnant rat uteri. Isolated uteri were stimulated by 5-HT or
electrical ®eld to investigate the contraction-inhibiting effect and the 5-HT1A activity of the a1A antagonists. Both receptor sub-
types are present in rat myometrium. 5-HT induced contractions were inhibited by the a1A antagonists. Besides shifting the
dose±response curve of 5-HT to the right, 5-MU decreased its maximal effect. The a1A antagonists inhibited electrical ®eld
stimulation-induced contractions. 5-HT1A blockade increased the maximal effect of 5-MU but did not change that of WB4101.
These results suggest that the contraction increase caused by 5-HT is mediated by a1A receptors. Serotonergic activity of a1
antagonists and especially a1A antagonists should be investigated as it may alter their ef®cacy and could interfere with their
side-effects. It is proposed that novel a1A antagonists should be designed with no 5-HT1A activity to achieve maximal relaxant
effect.
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Introduction
It has been clearly established that the adrenergic system plays a major
role in the regulation of myometrial contractility during pregnancy
(Marshall, 1981; Legrand and Maltier, 1986). Thus, a number of
attempts have been made to employ drugs that affect the adrenergic
system in the treatment of myometrial contractility disorders, with
special attention to premature labour. Currently, b2-adrenergic-
receptor (b2-AR) agonists are among the substances most frequently
used as tocolytics; however, controversy surrounds their ef®cacy,
especially when they are administered in prolonged therapies
(Lampert et al., 1993; Katz and Farmer, 1999; Rosenberg, 2001). In
the rat, besides the b2-ARs, the a1-adrenergic receptors (a1-ARs) have
been found to have a great impact on myometrial contractility
(Legrand and Maltier, 1986; ZupkoÂ et al., 1997). This gave the
initiative for a series of new investigations exploring the possible
scienti®c and therapeutic signi®cance of these adrenergic receptors.
In the pregnant rat, the a1/b2-AR density ratio increases towards the
end of pregnancy, this increase is mainly a consequence of an elevated
a1-AR density and not a decrease in b2-AR density (GaÂspaÂr et al.,
2001). Further studies have revealed that, of the three subtypes of a1-
ARs, it is the a1A subtype that is mostly responsible for the increase
(Ducza et al., 2002). It has also been reported that blockade of a1A-
ARs signi®cantly inhibits contractions of post-partum rat myometrium
in vitro (Ducza et al., 2001). Subsequent investigations showed that
a1A-AR antagonists signi®cantly increase the ef®cacy of the b2-AR
agonists, by raising their maximal contraction-inhibiting effect and
markedly decreasing their EC50 (Mihalyi et al., 2003).
The investigated a1-AR blockers, 2-(2,6-dimethoxyphenoxyethy-
l)aminomethyl-1,4-benzodioxane hydrochloride (WB 4101) and 5-
methylurapidil (5-MU) are known to have serotonergic properties too.
These substances bind to serotonin1A (5-HT1A) receptors and exert an
agonist effect on them (Schoeffter and Hoyer, 1988; Eltze et al., 1991;
Moser, 1991; Chidlow et al., 2001).
Data have previously been published on the interactions between 5-
HT1A-receptor agonists and a1-AR subtypes (Castillo et al., 1993).
The aim of the present study was therefore to clarify whether the
serotonergic activities of these subtype-selective a1-AR antagonists
have any in¯uence on their uterus-relaxant effect.
Materials and methods
All parts of the study involving animal subjects were conducted with the
approval of the Ethical Committee of Animal Experiments of the University of
Szeged (registration number: 1-74-8/2002).
Mating of the animals
Mature female (180±200 g) and male (240±260 g) Sprague±Dawley (SPRD)
rats were mated in a special mating cage. A metal door, movable by a small
electric engine, separated the rooms for the male and female animals. A timer
controlled the function of the engine. Since rats are usually active at night, the
separating door was opened before dawn. Within 4±5 h after the possible
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mating, vaginal smears were taken from the female rats, and a sperm search was
performed under a microscope at a magni®cation of 1200 times. If the search
proved positive, or when smear taking was impossible because of an existing
vaginal sperm plug, the female rats were separated and were regarded as ®rst-
day pregnant animals.
Reverse-transcription polymerase chain reaction (RT±PCR)
studies
RT±PCR was utilized to determine mRNA expression of the 5-HT1A receptors
and the a1A-ARs.
Tissue isolation
Female SPRD rats (250±300 g) were killed by cervical dislocation on day 22 of
gestation (end-term). Uterus tissue was rapidly removed. Two myometrial rings
from both horns of the uterus were sliced out and prepared for isolated tissue
experiments. The remainder was dissected in ice-cold saline (0.9% NaCl)
containing 2 U/ml of recombinant ribonuclease inhibitor (RNasin, Promega,
UK). The samples were frozen in liquid nitrogen and then stored at ±70°C until
total RNA extraction.
Total RNA preparation
Total cellular RNA was isolated by extraction with guanidinium thiocyanate-
acid±phenol±chloroform, according to the procedure of Chomczynski and
Sacchi (Chomczynski and Sacchi, 1987). After precipitation with isopropanol,
the RNA was treated with RNase-free DNase I for 30 min at 37°C, re-extracted
with phenol, precipitated with ethanol, washed with 75% ethanol and then
resuspended in diethyl pyrocarbonate-treated water. The RNA concentration
was determined by optical density measurements at 260 nm.
RT±PCR
RNA (0.5 mg) was denaturated at 70°C for 5 min in a reaction mixture
containing 20 U of RNase inhibitor (Hybaid, UK), 200 mmol/l dNTP (Sigma-
Aldrich, Hungary), 20 mmol/l oligo(dT) (Hybaid, UK) in 50 mmol/l Tris±HCl,
pH 8.3, 75 mmol/l KCl and 5 mmol/l MgCl2 in a ®nal reaction volume of 19 ml.
After the mixture had been cooled to 4°C, 20 U of M-MLV reverse
transcriptase, RNase H Minus (Promega, UK) was added, and the mixture
was incubated at 37°C for 60 min and then at 72°C for 10 min.
The PCR was carried out with 5 ml of cDNA, 25 ml of ReadyMix REDTaq
PCR reaction mix (Sigma-Aldrich, Hungary) and 50 pmol/l sense and antisense
primer. The primer sequences to amplify the 5-HT1A(-receptor mRNA) were
5¢-CCA AAG AGC ACC TTC CTC TG-3¢ (for the forward primer) and 5¢-TAC
CAC CAC CAT CAT CAT CA-3¢ (for the reverse primer); these primers were
anticipated to generate a 388 bp PCR product (Albert et al., 1989). The primers
for the a1A-AR were 5¢-GTA GCC AAG AGA GAA AGC CG-3¢ and 5¢-CAA
CCC ACC ACG ATG CCC AG-3¢; these primers generated a 212 bp PCR
product (Sco®eld et al., 1995). A rat GAPDH probe was used as internal control
in all samples (Tso et al., 1985)]. The PCR was performed with a PCR Sprint
thermal cycler (Hybaid Corp., UK), with the following cycle parameters: after
initial denaturation at 95°C for 3 min, the reactions were taken through 35
cycles of 1 min at 95°C, 1 min annealing at 55°C, and 1 min at 72°C. After the
last cycle, incubation was continued for 3 min at 72°C, followed by lowering of
the temperature to 4°C. PCR products were used immediately or stored at
±70°C. The PCR products were visualized by performing the electrophoresis on
ethidium bromide (Sigma-Aldrich, Hungary) containing gel. Densitometric
scanning of the gel was performed with the KODAK EDAS290 system
(Csertex Ltd, Hungary). The 5-HT1A/GAPDH ampli®cation ratio was
calculated for each RNA pool. The a1A-AR/GAPDH ratio was also calculated
for each RNA pool.
Isolated tissue studies
Preparation of the tissues
Uterus rings were taken from the above-mentioned 22 day pregnant SPRD rats.
Two muscle rings were sliced from both horns of the uterus and mounted
vertically between two platinum electrodes in a tissue bath containing 10 ml of
de Jongh buffer solution (composition in mmol/l: NaCl, 137; KCl, 3; CaCl2, 1;
MgCl2, 1; NaHCO3, 12; NaH2PO4, 4; glucose, 6; pH 7.41). The temperature of
the tissue bath was set to and maintained at 37°C, and carbogen (95% O2 + 5%
CO2) was perfused continuously through the bath. Tissue samples were
equilibrated under these conditions for 90 min before the experiments were
started. The initial tension of the uterus rings was set to 1.5 g, which dropped
spontaneously to 0.5 g by the end of the equilibration period.
Determination of contractility changes (5-HT stimulation).
Noncumulative concentration±response curves were constructed for 5-HT
(Sigma-Aldrich, St Louis, MO, USA). The spontaneous contractions of the
tissues were recorded for 4 min.
5-HT was then administered to the bath and the contractions were recorded
for another 4 min. This procedure was repeated after a 5 min regeneration
period during which the tissue samples were washed four times with de Jongh
buffer solution. The 5-HT concentration range was 1310±9±3310±6 mol/l.
Spontaneous contractions were regarded as the control. The contraction
increase caused by 5-HT was expressed as a percentage of the control
contractions.
In the following step noncumulative concentration±response curves were
constructed for 5-HT, but this time in the presence of the subtype-selective a1A-
AR antagonists, WB4101 (Tocris-Cookson, Bristol, UK) (Morrow and Creese,
1986; Hieble et al., 1995) and 5-MU (Sigma-Aldrich, USA) (Gross et al., 1988;
1990; Valenta et al., 1990) at both 1310±7 and 1310±6 mol/l. The procedure
was similar to that described above, except recording of the control
contractions was preceded by a 5 min incubation with the a1A-AR antagonists.
Each concentration±response curve was constructed by using newly removed
uterus samples. The reason for this was that, following a 30 min regeneration
period after the ®rst series of 5-HT stimulation, the changes in the contractions
caused by the same concentrations of 5-HT were different as the basal
contractions were smaller than in the ®rst series.
The tensions of the myometrial rings were measured with a strain gauge
transducer (SG-02; Experimetria Ltd, London, UK) and recorded with an
Isosys Data Acquisition System (Experimetria Ltd).
Electrical ®eld stimulation (EFS)
Noncumulative concentration±response curves were constructed for the a1A-
AR antagonists, WB4101 and 5-MU. Contractions were elicited by a digital
programmable stimulator (ST-02; Experimetria Ltd), using square pulses with a
duration of 150 ms and a frequency of 23.75 s. The stimulating potential in each
experiment was 40 V. After the previously described equilibration period, the
tissue samples were stimulated by EFS for 4 min and the contractions were
recorded and regarded as the control. The a1A-AR antagonists were then added
to the bath and the contractions were recorded for another 4 min. This
procedure was repeated after a 5 min regeneration period, during which the
Figure 1. The expression of uterine a1A-AR (212 bp) and 5-HT1A-receptor
(388 bp) mRNA on day 22 of pregnancy. Results of the RT±PCR study
demonstrate the expressions of a1A-AR mRNA and 5-HT1A-receptor mRNA
on day 22 of pregnancy in the rat. The receptor mRNA expression level was
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tissues were washed four times. Following this, noncumulative concentration±-
response curves were constructed for the a1A-AR antagonists in the presence of
1310±7 and 5310±7 M (S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-
yl)-2-phenylpropanamide (WAY100135) (Fletcher et al., 1993a; 1993b), a
subtype-selective 5-HT1A-receptor antagonist. The experimental design was
similar to the previous one, but the control phase was followed by a 5 min
incubation period with WAY100135. Here, and also in the previous case when
5-HT was used to elicit contractions, newly removed uterus rings were used for
each concentration±response curve.
Data analysis
The areas under the curves (AUCs) were analysed statistically with Prism 2.01
software (GraphPad Software, San Diego, CA, USA), using ANOVA with the
Neuman±Keuls' post hoc test. Data are given as the mean 6 SEM and in all
experiments n = 10.
Results
Receptor mRNA expression
We demonstrated the expression of a1A-AR mRNA and 5-HT1A-
receptor mRNA on day 22 of pregnancy in the rat by RT±PCR. Both
receptor subtypes are present in pregnant rat myometrium (Figure 1).
Effects of a1A-AR antagonists on 5-HT-induced
contractions
5-HT increased the contractions of pregnant rat myometrium in a
concentration- dependent manner (Figure 2). The EC50 and the
maximal effect of 5-HT are presented in the ®rst row of Table I.
WB4101 (1310±7 mol/l) shifted the concentration±response curve of
5-HT to the right (Figure 2), signi®cantly increasing its EC50, but not
markedly altering its maximal effect (Table I, row 2). When WB4101
was present at 1310±6 mol/l the right-shift of the concentration±-
response curve of 5-HT was more explicit (Figure 2) and its EC50
increased further, but the maximal effect was not altered (Table I, row
3).
Similar phenomena were observed when the concentration±-
response curve of 5-HT was constructed in the presence of 5-MU
(1310±7 mol/l). The a1A-AR antagonist shifted the curve to the right
(Figure 3) and, as in the previous case, the EC50 of 5-HT was
signi®cantly elevated whilst there was no signi®cant change on the
maximal effect (Table I, row 4).
Interestingly, when 5-MU was applied at 1310±6 mol/l concentra-
tion the dose±response curve of 5-HT was again shifted to the right
(Figure 3), but the increase in the EC50 was accompanied by a
signi®cant decrease in the maximal effect of 5-HT (Table I, row 5).
Changes in contractility caused by a1A-AR blockade and
simultaneous 5-HT1A-receptor blockade
WB4101 inhibited EFS-elicited contractions in a concentration-
dependent manner (Figure 4). The EC50 and the maximal contrac-
tion-inhibiting effect are presented in the ®rst row of Table II.
5-HT1A-receptor blockade with WAY100135 (1310±7 mol/l) did
not change the contraction-inhibiting features of WB 4101. The 5-
Figure 2. Concentration±response curve of 5-HT alone and in the presence
of different concentrations of the subtype-selective a1A-AR antagonist WB
4101. 5-HT (squares) increased the contractility of the pregnant rat
myometrium in a concentration-dependent manner. 1310±7 mol/l WB 4101
shifted the concentration±response curve of 5-HT to the right (circles). When
WB 4101 was present at 1310±6 mol/l the right-shift of the curve was more
explicit (triangles). The y-axis represents the contractions expressed as
percentages of the basal contractions.
Figure 3. Concentration±response curve of 5-HT alone and in the presence
of different concentrations of the subtype-selective a1A-AR antagonist 5-
MU. 5-HT (squares) increased the contractility of the pregnant rat
myometrium in a concentration-dependent manner. When the
concentration±response curve of 5-HT was constructed in the presence of
1310±7 mol/l 5-MU (circles), the a1A-AR antagonist shifted the curve to the
right. On increasing the concentration of 5-MU to 1310±6 mol/l, the
dose±response curve of 5-HT was further shifted to the right (triangles). The
y-axis represents the contractions expressed as percentages of the basal
contractions.
Table I. Changes in the contraction increasing effect of serotonin (5-HT) in the presence of different concentrations of the subtype-selective a1A-AR
antagonists WB 4101 and 5-methylurapidil (5-MU)
EC50 (mol/l) (mean 6 SEM) Level of signi®cance Emax (%) (mean 6 SEM) Level of signi®cance
1 5-HT 8.0310±8 6 1.9310±8 ± 437.9 6 38.9 ±
2 5-HT + WB4101 1310±7 mol/l 4.5310±7 6 1.1310±7 * 424.0 6 54.8 NS
3 5-HT + WB4101 1310±6 mol/l 5.8310±7 6 1.8310±7 * 328.7 6 66.3 NS
4 5-HT + 5-MU 1310±7 mol/l 3.3310±7 6 6.2310±8 *** 384.4 6 40.7 NS
5 5-HT + 5-MU 1310±6 mol/l 3.9310±7 6 4.8310±8 *** 301.2 6 26.2 *
NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001.
EC50, the concentration of 5-HT producing 50% of its maximal contraction-increasing effect. Emax, the maximal contraction-increasing effect of 5-HT in the
system.
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HT1A-receptor antagonist had no effect on the shape or the position of
the concentration±response curve of WB4101 (Figure 4). No signi®-
cant change was observed regarding the EC50 or the maximal
contraction-inhibiting effect of WB4101 (Table II, row 2). Raising the
concentration of the 5-HT1A-receptor antagonist to 5310±7 mol/l did
not signi®cantly alter the dose±response curve of WB4101 either
(Figure 4). The EC50 and the maximal contraction-inhibiting effect of
the a1A-AR antagonist remained unchanged (Table II, row 3).
The other subtype-selective a1A-AR antagonist, 5-MU, also proved
to inhibit the EFS- induced contractions of the isolated rat
myometrium in a dose-dependent way (Figure 5). The EC50 and
maximal inhibitory effect are given in the fourth row of Table II. In the
presence of WAY100135 (1310±7 mol/l) the concentration±response
curve of 5-MU was shifted slightly to the right (Figure 5), but no
essential change was observed in the EC50. The maximal contraction-
inhibiting effect of 5-MU showed an increase in the presence of
WAY100135 (1 3 10±7 mol/l), but statistically this change did not
prove to be signi®cant (Table II, row 5). When the 5-HT1A-receptor
antagonist was applied at 5310±7 mol/l concentration the
concentration±response curve of 5-MU was shifted further to the
right (Figure 5). The EC50 of 5-MU did not display a considerable
deviation in this case either, but the maximal contraction-inhibiting
effect of the a1A-AR antagonist increased to a greater degree, and this
increase was statistically signi®cant (Table II, row 6).
Discussion
Recent studies have shown that the subtype-selective a1A-AR
antagonists have a pronounced relaxant effect on the pregnant rat
uterus (Ducza et al., 2002) and they appreciably potentiate the effects
of b2-AR agonists (Mihalyi et al., 2003). These promising results may
afford an adequate basis for a new approach in the treatment of
preterm delivery, which is still a leading cause of perinatal morbidity
and mortality, costing approximately 13 million lives annually
(Althabe et al., 1999).
The existence of a close relationship between the serotonergic and
adrenergic systems has been supported by a number of studies
(Castillo et al., 1993). However, the data available concerning this
relationship regarding the myometrium are limited, and the informa-
tion relating to the different receptor subtypes involved in the
relationship between the two systems is incomplete. With regard to the
severity of the problem of preterm labour and the possible bene®ts of
the use of subtype-selective a1-AR antagonists, it seemed to be
particularly important to elucidate the role of the serotonergic features
of these substances.
5-HT itself increased the contractility of the pregnant rat
myometrium. Both a1A-AR antagonists inhibited the contraction-
increasing effect of 5-HT. When 5-HT was administered in the
presence of 1310±7 mol/l WB4101, its concentration±response curve
Table II. Changes in the contraction inhibiting effects of the subtype-selective a1A-AR antagonists WB 4101 and 5-methylurapidil (5-MU) in the presence of
different concentrations of the 5-HT1A-receptor antagonist WAY100135
EC50 (mol/l) (mean 6 SEM) Level of signi®cance Emax (%) (mean 6 SEM) Level of signi®cance
1 WB4101 2.5310±5 6 5.2310±6 ± 76.5 6 6.4 ±
2 WB4101 + WAY100135 1310±7 mol/l 2.5310±5 6 6.9310±6 NS 76.2 6 18.4 NS
3 WB4101 + WAY100135 5310±7 mol/l 2.0310±5 6 2.8310±6 NS 73.6 6 5.6 NS
4 5-MU 2.9310±6 6 9.3310±7 ± 53.7 6 9.7 ±
5 5-MU + WAY100135 1310±7 mol/l 3.7310±6 6 8.9310±7 NS 78.23 6 11.51 NS
6 5-MU + WAY100135 5310±7 mol/l 3.8310±6 6 8.6310±7 NS 89.6 6 5.4 *
NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001.
EC50, the concentration of the a1A-AR antagonists producing 50% of their maximal contraction inhibiting effect; Emax: the maximal contraction-inhibiting
effect of the a1A-AR antagonists in the system.
Figure 5. Contraction-inhibiting effect of 5-MU alone and in the presence of
1 3 10±7 and 5 3 10±7 mol/l WAY100135. The subtype-selective a1A-AR
antagonist 5-MU (squares) inhibited the EFS-induced contractions of the
isolated rat myometrium in a dose-dependent way. In the presence of 1310±7
mol/l WAY100135 (circles) the concentration±response curve of 5-MU was
slightly shifted to the right and the top of the curve was higher, though these
changes were not signi®cant. When the 5-HT1A-receptor antagonist was
applied at 5310±7 mol/l (triangles) the concentration±response curve of 5-
MU was further (but still not signi®cantly) shifted to the right; however, the
top of the curve was signi®cantly elevated. The y-axis represents the
contractions expressed as percentages of the control contractions elicited by
EFS.
Figure 4. Contraction-inhibiting effect of WB 4101 alone and in the
presence of different concentrations of the 5-HT1A-receptor antagonist
WAY100135. WB 4101 alone (squares) inhibited the EFS-elicited
contractions in a concentration-dependent manner. 5-HT1A-receptor blockade
with 1310±7 mol/l WAY100135 changed neither the shape nor the position
of the concentration±response curve of WB 4101 (circles). Elevation of the
concentration of the 5-HT1A-receptor antagonist to 5310±7 mol/l did not
signi®cantly alter the dose±response curve of WB 4101 either (triangles).
The y-axis represents the contractions expressed as percentages of the
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was shifted to the right, and when the concentration of WB4101 was
increased by one magnitude the shift was even greater. In parallel with
this, the maximal effect of 5-HT did not change signi®cantly. These
results suggest that there is a competitive antagonism between 5-HT
and WB4101. Furthermore, since WB4101 binds to a1A-ARs with
greater af®nity than to 5-HT1A receptors, these results suggest that the
contractility-increasing effect of 5-HT in the rat myometrium is (at
least partially) mediated by a1A-ARs. Similarly, when the
concentration±response curve of 5-HT was constructed in the presence
of 1310±7 mol/l 5-MU, the curve was moved to the right, and elevation
of the concentration of 5-MU to 1310±6 mol/l further increased this
right-shift. However, when 5-HT was applied together with 5-MU, the
coadministration led not only to a right-shift of the curve but also to a
decrease in the maximal effect of 5-HT. These observations suggest
that the serotonergic activities of the two a1A-AR antagonists differ
substantially. To determine the difference between the substances in
this respect, the dose±response curves of the a1A-AR antagonists were
constructed alone and in the presence of the subtype-selective 5-HT1A-
receptor antagonist WAY100135, EFS being used to elicit contrac-
tions. The contraction-inhibiting characteristics of WB4101 were not
changed when the 5-HT1A-receptor antagonist at 1310±7 mol/l was
added. When a ®ve times larger concentration of WAY100135,
5310±7 mol/l, was applied, it did not alter the uterus-relaxant effect
either. This again indicates that WB4101 inhibits contractions of the
pregnant rat myometrium through a1A-ARs. Since WB4101 inhibited
the 5-HT-induced contractions, these results strengthen the hypothesis
that 5-HT-elicited contractions may also be mediated by a1A-ARs in
the rat myometrium.
In contrast, the contraction-inhibiting properties of 5-MU changed
when it was applied together with the 5-HT1A-receptor antagonist.
Even in the presence of 1310±7 mol/l WAY100135, 5-MU exhibited
an increased maximal contraction-inhibiting effect. Elevation of the
concentration of the 5-HT1A-receptor antagonist to 5310±7 mol/l
resulted in an even greater increase in the maximal effect of 5-MU,
this increase proving to be statistically signi®cant.
Impeding the serotonin agonist effect of 5-MU by 5-HT1A-receptor
blockade raised the maximal contraction-inhibiting effect of 5-MU to
89.6 6 5.4%, which is even higher than the maximal effect of
WB4101, 76.5 6 6.4%. These results suggest that the serotonergic
activity of 5-MU is more pronounced than that of WB4101. The
different chemical structures may offer an explanation for the
noteworthy difference between the serotonergic properties of the
two a1A-AR antagonists. It seems probable that 5-MU has a dual
in¯uence on the pregnant rat myometrium: a dominant a1A-AR
antagonist effect that inhibits contractions, and a less expressed
agonist effect on the 5-HT1A receptors that increases the contractility
of the pregnant rat uterus.
Although subtype-selective a1A-AR antagonists are not yet used in
pharmacotherapeutic practice, the data obtained on these substances
so far suggests that they could improve the armamentarium of
tocolytic agents. The results of the present study allow the assumption
that in the future, subtype-selective a1A-AR antagonists should be
designed with no or only negligible 5-HT1A-agonist activity so as to
provide a maximal contraction-inhibiting effect.
Since the demand for highly speci®c, subtype-selective substances
is great not only in the ®eld of obstetrics but in other areas as well, the
serotonergic activities of a1 antagonists and especially the a1A
antagonists should be investigated, as this may alter the ef®cacy of
such substances and could interfere with their side-effects.
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